



RECEIVED

FEB 7 2003

TC 1700

RECEIVED

FEB 10 2003

Docket TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Hu et al.

Application No.: 09/257,272-Conf. #1980

Group Art Unit: 1647

Filed: December 23, 1998

Examiner: R. Landsman

For: Vascular Endothelial Growth Factor 2

**TERMINAL DISCLAIMER**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Your Petitioner, Melissa J. Pytel, represents that she holds the position of Attorney of Human Genome Sciences, Inc. (hereinafter the "Assignee"), which is the owner of the entire right, title and interest in and to the above-identified application by virtue of an assignment which was recorded on August 18, 1998, at Reel 9440, Frame 0794 in Application Serial No. 08/999,811, filed December 24, 1997.

The Assignee hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of U.S. Patent No. 5,932,540, which issued on August 3, 1999, and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 5,932,540.

The Assignee further agrees that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns.

The Assignee does not disclaim any terminal part of the patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent No. 5,932,540 in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of their full statutory term, except for the separation of legal title stated above.

02/19/2003 DTHURMS 00000002 083425 0225127E  
01 FC:1814 11950159

31


Petitioner hereby confirms that she has reviewed the assignment and, to the best of her knowledge and belief, the entire title is in the Assignee seeking to take action in this matter and that she is empowered to act on behalf of Human Genome Sciences, Inc.

The fee under 37 C.F.R. § 1.20(d) for processing this Terminal Disclaimer is believed to be \$110.00. The Commissioner is hereby authorized to charge the required fee to Deposit Account No. 08-3425. A Fee Transmittal with appropriate fee is enclosed.

Petitioner hereby declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 4<sup>th</sup> day of February, 2003.

HUMAN GENOME SCIENCES, INC.

By   
Melissa J. Pytel

Registration No.: 41,512  
HUMAN GENOME SCIENCES, INC.  
9410 Key West Avenue  
Rockville, Maryland 20850  
(301) 610-5764